IRISH TIMES.COM: Four out of every five Irish men diagnosed with prostate cancer will still be alive in five years. READ MORE>
Improvements in survival rates are being attributed to increased screening, better surgery and multidisciplinary care.
Posted in Survival, tagged better surgery, cancer research, catheter, increased screening, IRISH TIMES.COM, multidisciplinary care, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate survival rates on September 12, 2010 | Leave a Comment »
PROSTABLOG NZ: If only 3% of US men diagnosed with prostate cancer die, what’s happening in NZ, where the proportion is 20%?
The 3% figure pops up in Mike Scott‘s latest discussion on PSA testing for prostate cancer, when he says:
…the number of men in America who die of prostate cancer today is believed to be significantly less than three for every 100 men diagnosed. (New Prostate Cancer Infolink)
Compare that with NZ, where about 3000 prostate cancer diagnoses are registered each year – and 600 men die each year. That’s 20%.
Does the NZ Ministry of Health have some explaining to do?
Read Mike’s discussion HERE>
Posted in OFFICIAL BODIES, PROSTATE CANCER, Public health system, Survival, tagged breast, cancer screening programmes, cancer survival rates, cervical, coloectal, Ethnic minorities, Five-year cancer survival rates, health care, health system, Lung, Maori cancer survival, Ministry of Health, NZ MOH annual report, NZ prostate cancer survival, Pacific people, Pacific women, prostate, treating cancer on October 21, 2009 | Leave a Comment »
PROSTABLOG NZ: The survival rate for prostate cancer patients in NZ increased more than 12% in the seven years to 2006, according to the Ministry of Health. READ MORE>
The prostate cancer survival gain is the best of five major cancer sites (prostate, breast, coloectal, cervical and lung), says the Ministry’s annual report released this week.
Maori continue to show poor results.
On cancer survival, the report says:
Cancer survival is a key outcome measure of cancer control and provides useful insights into the effectiveness of health care in detecting and treating cancer. Five-year cancer survival rates are a direct measure of the effectiveness of the health system in treating cancer.
The five-year relative survival rate has increased for all five major cancer sites.
This increase was in the region of 5–6 percent for colorectal, breast and cervical cancers and over 12 percent for prostate cancer in the seven years since 1997/98.
The survival rate for lung cancer is significantly less than for other cancer sites and has improved the least.
Five-year relative survival rates show Maori at a marked disadvantage compared with the non-Maori/non-Pacific ethnic group for five selected cancer sites.
Of all ethnic groups, Pacific people show the lowest relative survival rates for female breast and cervical cancers.
Efforts to increase the number of Pacific women being screened through cancer screening programmes should help to identify greater numbers of women in need of cancer treatment in the future.
Posted in PROSTATE CANCER, PROSTATE RESEARCH, PROSTATE RISKS, Socio-economic status, Survival, tagged better survival, cancer research, HULIQ NEWS:, low socio-economic status, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer survival, prostate cancer treatments, prostate treatment, prostate treatment debate, Screening debate, socio-economics and prostate, Swiss researchers on September 29, 2009 | Leave a Comment »
Posted in PROSTATE CANCER, PROSTATE RESEARCH, Survival, tagged better survival rates, cancer research, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, Screening debate, URO TODAY on September 18, 2009 | Leave a Comment »
Posted in Age factors, PROSTATE CANCER, PROSTATE RESEARCH, Survival, tagged age, Age at diagnosis, cancer research, five-year survival rate, French study, prostablog, prostate, prostate blog, PROSTATE CANCER, URO TODAY on August 12, 2009 | Leave a Comment »
URO TODAY: The five-year survival rate for prostate cancer patients differs according to age at diagnosis, increasing from 70% in men age under 55 years at diagnosis to 83% in men age over 65 years, according to a French study. READ MORE>
NOTE: You need to register with the Uro Today site to read this. It doesn’t cost anything.
Posted in Hormone-refactory, Immunotherapy, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, Survival, Treatment news, tagged advanced prostate cancer, advanced prostate cancer treatment, cancer research, Dr James Watson, Dr Richard Forster, immune system, immunology, leading NZ scientist, NZ Prostate Cancer Foundation, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, prostate-specific antigen, Provenge treatment, PSA, PSA test, University of California on August 3, 2009 | Leave a Comment »
PROSTABLOG NZ: A leading NZ scientist has discovered a novel compound he believes will suppress the prostate cancer that is killing him.
Dr James Watson (right) – a former professor at the University of California, now back in NZ – discovered too late he has advanced cancer, so has embarked (with a fellow Kiwi scientist, who also has advanced prostate cancer) on a research project to stop his deadly disease.
He believes he has identified a treatment that will stimulate his immune system to fight the cancer, which has spread beyond his prostate.
He has decided to test the compound on himself, with the assistance of another eminent Auckland medical specialist.
His quest is driven partly by the altruism of finding a viable treatment for all men whose prostate cancer moves to a stage that defies treatment, and partly by his anger at not being diagnosed early when the disease could have been treated easily.
He saw several GPs before one offered him a PSA test, by which time his level was a lethal 987.
He and colleague Dr Richard Forster, an expert on immunology and plant biology, have set up a company to develop their discoveries.
They revealed their progress at the annual conference of the NZ Prostate Cancer Foundation in Napier.